title: Plasma-exchange in chronic peripheral neurological disorders.
abstract: We investigated 19 patients affected by chronic peripheral neurological disorders treated with therapeutic plasma exchange (TPE) to verify the efficacy of the therapeutic protocol used in these diseases. Every patient was clinically considered after 5 TPE. Those who showed an improvement started chemotherapy and continued TPE at the rate of 2 procedures/week for 2 weeks, then 1 procedure/week for 1 month and finally 1 procedure every 2 weeks for 2 months. Intravenous immunoglobulins (IVIg) were infused at the end of apheretic treatment in one of the patients affected by neurological disorders due to monoclonal gammopathy undetermined significance. HCV-positive patients with cryoglobulins were treated with alpha-interferon (alpha-IFN) for 6 months before TPE. Eleven patients (58%) had a symptomatic improvement, 2 (1.5%) stopped TPE treatment owing to side effects and 6 (31.5%) did not respond to apheretic therapy. In order to improve the advantages of TPE we suggest using IVIg at the end of apheretic therapy, while in HCV-positive patients, at least one year of alpha-IFN therapy is required before initiating TPE.
authors: Servizio Immunotrasfusionale, Azienda Ospedaliera S. Maria degli Angeli, Pordenone, Italy.
authors: G
authors: G
authors: Mazzi
authors: A
authors: A
authors: Raineri
authors: M
authors: M
authors: Zucco
authors: P
authors: P
authors: Passadore
authors: A
authors: A
authors: Pomes
authors: B M
authors: BM
authors: Orazi
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000150:complications* / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000628:therapy*; D010951:Plasma Exchange / Q000009:adverse effects
chemical_list: D016756:Immunoglobulins, Intravenous